leadf
logo-loader
viewDyadic International Inc

Dyadic in high profile collaboration with China’s pharma giant Jiangsu Hengrui Medicine for biologic drug development

Jiangsu Hengrui will develop biologic drugs efficiently and at low cost by using Dyadic’s proprietary C1 gene expression platform

Dyadic International Inc - Dyadic in a high profile collaboration with China’s pharma giant Jiangsu Hengrui Medicine for biologic drug development
Dyadic CEO Mark Emalfarb said the collaboration highlights the appeal of C1's value proposition, "producing cell lines at higher expression levels and lower cost," to address global demand for more efficient biomanufacturing processes of biologic vaccines and drugs

Dyadic International Inc (NASDAQ:DYAI) announced a collaboration on Thursday with Jiangsu Hengrui Medicine Company Limited (SSE:600276) to channel Dyadic’s proprietary C1 gene expression system to develop selected Hengrui biologic drugs.

Headquartered in China, the Jiangsu Hengrui Medicine Company clocked up revenue of over $3.3 billion in 2019. It has six new molecular entities approved in China as well more than 30 programs in clinical development in China, Australia EU and the US across oncology, anesthesiology, analgesics, autoimmune, metabolic and cardiovascular areas.

"We are very excited to partner with Hengrui, one of the most innovative and inventive global biopharmaceutical companies,” Dyadic CEO Mark Emalfarb said in a statement.

READ: Dyadic reveals rising R&D revenue in 2Q results from a bevy of research collaborations

“This collaboration also highlights the appeal of C1's value proposition, producing cell lines at higher expression levels and lower cost, to address global demand for more efficient biomanufacturing processes of biologic vaccines and drugs. We are looking forward to a successful collaboration with Hengrui," he added.

Dr Lianshan Zhang, who is the president of R&D at Hengrui, said the group is interested in Dyadic's C1 technology, which has potential to help the company produce biotherapeutics in a “more cost-effective fashion.”

“As a result, we are leveraging our combined expertise and working closely with Dyadic as we share their vision of creating biomedicines to benefit patients globally," Dr Zhang added.

Founded in 1979, Dyadic engages in the large-scale manufacture of low-cost enzymes and other proteins for US and international markets. It leverages its proprietary C1 gene expression system - a fungal expression technology for producing enzymes - to help bring biologic vaccines, therapeutic enzymes, proteins, biosimilars and drugs to market faster and at a lower cost.

Dyadic has patented its proprietary filamentous fungus, Myceliophthora thermophila, nicknamed C1 and the associated molecular tools used to engineer the C1 cells to express and manufacture large volumes of low-cost biologic products such as enzymes and proteins. The C1 fungus is a living cell that has been bioengineered by Dyadic scientists for more than two decades.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: Dyadic International Inc

Price: 7.14 USD

NASDAQ:DYAI
Market: NASDAQ
Market Cap: $196.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Dyadic working with global research partners to express potential...

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb tells Proactive the Florida-based biotech is 'delivering on its promises.' Emalfarb says it saw a busy first quarter where the company stepped up in the global fight against the coronavirus pandemic. Emalfarb says among its recent...

on 05/15/2020

2 min read